Scarica l'app Stockscreener
3.28
0.91%
-0.03
Precedente Chiudi:
$3.31
Aprire:
$3.34
Volume 24 ore:
210.44K
Relative Volume:
0.36
Capitalizzazione di mercato:
$181.23M
Reddito:
$163.78M
Utile/perdita netta:
$25.88M
Rapporto P/E:
5.0462
EPS:
0.65
Flusso di cassa netto:
$-28.66M
1 W Prestazione:
+1.23%
1M Prestazione:
+11.56%
6M Prestazione:
-41.64%
1 anno Prestazione:
-64.31%
Intervallo 1D:
$3.25
$3.375
Intervallo di 1 settimana:
$3.15
$3.40
Portata 52W:
$2.645
$9.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Nome
Voyager Therapeutics Inc
Settore
Industria
Telefono
857-259-5340
Indirizzo
75 HAYDEN AVENUE, LEXINGTON, MA
Confronta VYGR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.275 | 181.50M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.07 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.48 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.50 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.58 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.76 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-02 | Iniziato | Citigroup | Buy |
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-10-16 | Iniziato | Leerink Partners | Outperform |
| 2024-03-26 | Iniziato | Guggenheim | Buy |
| 2024-03-19 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-07 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | Iniziato | Truist | Buy |
| 2023-03-10 | Iniziato | Oppenheimer | Outperform |
| 2021-10-07 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Downgrade | BTIG Research | Buy → Neutral |
| 2021-02-03 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Iniziato | The Benchmark Company | Buy |
| 2020-02-06 | Iniziato | Oppenheimer | Outperform |
| 2018-11-15 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-09-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-02-02 | Iniziato | Morgan Stanley | Overweight |
| 2017-11-28 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2017-10-27 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-23 | Reiterato | Stifel | Buy |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-28 | Ripresa | Stifel | Buy |
Mostra tutto
Voyager Therapeutics Inc Borsa (VYGR) Ultime notizie
How high can Voyager Therapeutics Inc. stock price go in 2025Rapid return acceleration - jammulinksnews.com
What drives Voyager Therapeutics Inc. stock priceFree Capital Efficiency Planning - Autocar Professional
What analysts say about Voyager Therapeutics Inc. stockMarket-leading growth rates - jammulinksnews.com
Is Voyager Therapeutics Inc. a good long term investmentHigh-yield trading alerts - Autocar Professional
Voyager Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com
Why Voyager Therapeutics Inc. stock attracts strong analyst attentionFree Smart Money Stock Analysis - Newser
Voyager Therapeutics’ Promising Alzheimer’s Study: A Potential Game-Changer? - MSN
Voyager Therapeutics: A High-Conviction Biotech Play in the Tau-Targeting Alzheimer's Revolution - AInvest
Why did Voyager's net profit surge in Q4 2024 despite high operating expenses? - AInvest
Does Voyager Therapeutics Inc. stock pay reliable dividendsTrend Based Entry Alerts - beatles.ru
Baird Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
Voyager Therapeutics adds new gene therapy to Alzheimer’s program - BioWorld MedTech
Baird reiterates Outperform rating on Voyager Therapeutics stock with $18 price target - Investing.com Canada
Citi Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $11 - 富途牛牛
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease - GlobeNewswire
How Voyager Therapeutics Inc. stock performs during market volatilityDaily Top Gainers - Newser
Voyager Therapeutics Introduces New Program Targeting Genetic Risk Factor of Alzheimer's Disease - 富途牛牛
Voyager Therapeutics Launches New Gene Therapy Program Targeting APOE for Alzheimer's Disease Treatment - Quiver Quantitative
Voyager Therapeutics unveils APOE-targeting Alzheimer’s therapy program By Investing.com - Investing.com South Africa
Voyager Therapeutics unveils APOE-targeting Alzheimer’s therapy program - Investing.com
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewswire Inc.
What makes Voyager Therapeutics Inc. stock price move sharplyBreakout Setup Scanner - Newser
Allspring Global Investments Holdings LLC Buys 21,149 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of “Buy” from Brokerages - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Rhumbline Advisers - Defense World
Financial Comparison: Prime Medicine (NYSE:PRME) & Voyager Therapeutics (NASDAQ:VYGR) - Defense World
Voyager Therapeutics at H.C. Wainwright: Genetic Innovation in Focus By Investing.com - Investing.com Canada
Equities Analysts Offer Predictions for VYGR FY2026 Earnings - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspecti - GuruFocus
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference | VYGR Stock News - GuruFocus
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewswire
Millennium Management LLC Sells 60,935 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Squarepoint Ops LLC Decreases Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics Inc Azioni (VYGR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Voyager Therapeutics Inc Azioni (VYGR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sandrock Alfred | President and CEO |
Apr 02 '25 |
Sale |
3.43 |
10,885 |
37,336 |
430,931 |
1.74%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):